Publications
251
Citations
5,465
Est. group size
~22
Recurring co-author estimate
Active years
39
Publishing since 1988
Pierre Giglio is a physician-researcher focused on brain tumors, particularly glioblastoma and low-grade glioma, with work spanning clinical trials of new drugs, imaging-based monitoring of tumor response, and laboratory studies of tumor-neuron interactions. His research also touches on supportive care needs of brain tumor patients and, in some collaborative work, targeted therapy approaches in breast cancer.
Publication output has grown substantially over the past decade, rising from single digits per year around 2017-2018 to a notably higher and more variable pace since 2023.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial
Journal of Clinical Oncology · 2026
- Abstract PS5-03-11: Combinatorial EZH2 Inhibition and Dopamine D1 Agonism Suppresses Pro-Inflammatory Monocytes and TNBC Tumor Progression
Clinical Cancer Research · 2026
- Association of performance status, depression, and demographics with advance directive documentation in patients with glioblastoma
Supportive Care in Cancer · 2026
- Scatter factor/hepatocyte growth factor and c-Met in glioblastoma
Elsevier eBooks · 2026
- Abstract 7473: A novel dual-target strategy against TNBC: Combining EZH2 inhibition and dopamine D1 receptor activation to restore immune balance
Cancer Research · 2026
- Abstract 1488: Structure-guided dual targeting of EZH2 and dopamine D1 receptor suppresses TNBC growth and metastasis
Cancer Research · 2026
- Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial
Journal of Clinical Oncology · 2026
- Dissecting acute neuronal responses to glioblastoma using a dual-interface human iPSC neuronal culture platform
Acta Neuropathologica Communications · 2026
- Early Integrated Neuropsychological Care for Patients with Brain Metastases: A Randomized Controlled Trial (ATHENA Trial)
International Journal of Radiation Oncology*Biology*Physics · 2026
- Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology · 2025
- Papillary craniopharyngioma management in the era of BRAF and MEK inhibition
Journal of Neuro-Oncology · 2025
- Phase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naïve or Recurrent/Refractory Glioblastoma
Current Oncology · 2025
- Early Repeat Residual Resection Versus Adjuvant Therapy for Incompletely Resected Glioblastoma: A Case-Control Study
Neurosurgery · 2025
- Papillary Craniopharyngioma Management in the Era of BRAF and MEK Inhibition
Journal of Neurological Surgery Part B Skull Base · 2025
- A Human Neuronal Co-Culture System Reveals Early Tumor-Neuron Communication and Targetable Pathways in Glioblastoma
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Neuro-Oncology×49
- Journal of Clinical Oncology×11
- Neuro-Oncology Advances×9
- International Journal of Radiation Oncology*Biology*Physics×9
- Elsevier eBooks×7
- Sara Khan
Medicine · The Ohio State University
- Arnab Chakravarti
Medicine · The Ohio State University
- Jayeeta Ghose
Medicine · The Ohio State University
- Erin O’Farrell
Medicine · Indiana University
- J. Bradley Elder
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile